TCGA-PRAD patients were classified into the following four groups: ips_ctla4_neg_pd1_neg (CTLA4 and PD1 negative response); ips_ctla4_pos_pd1_neg (CTLA4 positive and PD1 negative response); ips_ctla4_neg_pd1_pos; and ips_ctla4_pos_pd1_pos (Figure 9C). The gene discussed is CTLA4; the disease is prostate adenocarcinoma.